3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Sarcoma
2
Xanthogranuloma, Juvenile
1
Wilms Tumor
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neurofibrosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neuroblastoma
1
Nerve Sheath Neoplasms
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Follicular
1
Inhibition, Psychological
1
Histiocytosis, Langerhans-Cell
1
Histiocytic Sarcoma
1
Hepatoblastoma
1
Glioma
1
Ependymoma
1
Central Nervous System Neoplasms
1
Interventions
Cyclophosphamide
11
Rituximab
10
Prednisone
8
Lenalidomide
8
Vincristine
7
Doxorubicin
7
Bendamustine Hydrochloride
6
obinutuzumab
5
Magnetic Resonance Spectroscopy
4
fludarabine
3
Whole-Body Irradiation
3
Specimen Handling
3
R-CHOP protocol
3
Cyclosporine
3
Biopsy
3
zanubrutinib
2
fludarabine phosphate
2
Radiotherapy
2
Prednisolone
2
Peripheral Blood Stem Cell Transplantation
2
Oxaliplatin
2
Mycophenolic Acid
2
Melphalan
2
Gemcitabine
2
Etoposide
2
Cytarabine
2
venetoclax
1
umbralisib
1
treosulfan
1
tazemetostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Follicular
×
tazemetostat
×
30 days
×
Clear all
NCT04224493
2026-06-01
SYMPHONY-1
Ipsen
Phase 3
Active not recruiting
599 enrolled